RobertLawrenceGottliebMD, PhD, FACC, FAST, FIDSA

Clinical Trials

• Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients Start of enrollment: 2018 Mar 20

  Active, not recruiting

  Phase 2

• Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia Start of enrollment: 2018 Jan 18

  Completed

  Phase 3

• Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia Start of enrollment: 2018 Mar 13

  Completed

  Phase 3

• A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation Start of enrollment: 2018 Apr 17

  Terminated

  Phase 3

• Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment Start of enrollment: 2020 Mar 15

  Completed

  Phase 3

• Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) Start of enrollment: 2020 Mar 06

  Completed

  Phase 3

• A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) Start of enrollment: 2020 Apr 15

  Completed

  Phase 2

• MSCs in COVID-19 ARDS Start of enrollment: 2020 Apr 30

  Terminated

  Phase 3

• A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 Start of enrollment: 2020 Apr 24

  Completed

  Phase 2

• A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia Start of enrollment: 2020 Jun 16

  Completed

  Phase 3

• A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness Start of enrollment: 2020 Jun 17

  Completed

  Phase 2, Phase 3

• Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting Start of enrollment: 2020 Sep 18

  Terminated

  Phase 3

• ACTIV-3: Therapeutics for Inpatients With COVID-19 Start of enrollment: 2020 Aug 04

  Completed

  Phase 3

• Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation Start of enrollment: 2020 Sep 14

  Completed

  Phase 1, Phase 2

• A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness Start of enrollment: 2020 Oct 29

  Completed

  Phase 2

• Cardiopulmonary Stress Testing (CPET) AlloSure Study Start of enrollment: 2020 May 21

  Recruiting

• The ARIES HeartMate 3 Pump IDE Study Start of enrollment: 2020 Jul 14

  Completed

  Not Applicable

• A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive HCM) Start of enrollment: 2022 Aug 16

  Recruiting

• A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy Start of enrollment: 2022 Dec 14

  Active, not recruiting

  Phase 3

• Study of Obeldesivir in Nonhospitalized Participants With COVID-19 Start of enrollment: 2023 Feb 08

  Completed

  Phase 3

• Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness Start of enrollment: 2022 Nov 05

  Terminated

  Phase 3

• Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS) Start of enrollment: 2022 Jul 11

  Recruiting

  Not Applicable

• Levels of Inflammation in People With Cardiovascular Disease (POSEIDON) Start of enrollment: 2023 Nov 15

  Enrolling by invitation

• NAN-101 in Patients With Class III Heart Failure Start of enrollment: 2019 Nov 20

  Recruiting

  Phase 1

• APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) Start of enrollment: 2019 Sep 04

  Active, not recruiting

  Phase 3

• Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy

  No longer available

• Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)

  Approved for marketing

• Join now to see all